Main Article Content
Objective: To describe the nephrotoxicity characteristics of patients using Colistin at Thong Nhat Hospital.
Subjects and methods: Retrospective cohort study on 116 patients at Thong Nhat Hospital who were assigned to take colistin between June 1st, 2020 and December 31st, 2020.
Results: Patients using colistin alone accounted for 30.17%. The majority of patients were treated with a combination of two antibiotics (colistin and another antibiotic). Nephrotoxicity accounted for
20.69% of the total studied patients. Median time to onset of nephrotoxicity in study patients was 8.5 days with interquartile range 5.5-15 days. The time range of onset of toxicity was mainly from
8 to 14 days, accounting for 45.83%. Distribution of patients with nephrotoxicity with the level of “Risk” accounted for the highest rate with 58.33%. There were 7 patients (29.17%) recovered during
treatment, 2 patients (8.33%) had to undergo emergency dialysis.
Conclusion: Nephrotoxicity accounted for 20.69%. The duration of onset of toxicity was mainly 8 to 14 days. Distribution of patients with nephrotoxicity with the level of “Risk” accounted for the highest rate with 58.33%.
 Ordooei JA, Shokouhi S, Sahraei Z, A review on colistin nephrotoxicity, Eur JClin Pharmacol., 2015; 71(7): 801-810.
 Balkan II, Dogan M, Durdu B et al., Colistin nephrotoxicity increases with age, Scand J Infect Dis., 2014; 46(10): 678-685.
 Kwon JA, Lee JE, Huh W et al., Predictors of acute kidney injury associated with intravenous colistin treatment, Int J Antimicrob Agents., 2010; 35(5): 473-477.
 Ko HJ, Jeon MH, Choo EJ et al., Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin, Nephron Clin Pract., 2011; 117(3): c284-288.
 Lee YJ, Wi YM, Kwon YJ et al., Association between colistin dose and development of nephrotoxicity, Crit Care Med., 2015; 43(6): 1187-1193.
 Lopes JA, Jorge S, The RIFLE and AKIN classifications for acute kidney injury: a critical and comprehensive review, Clinical Kidney Journal, 2013; 6(1): 8-14.
 Shahbazi F, Dashti KS, Colistin: efficacy and safety in different populations, Expert Rev Clin Pharmacol., 2015; 8(4): 423-48.
 Temocin F, Erdinc S, Tulek N et al., Incidence and Risk Factors for Colistin-Associated Nephrotoxicity, Jpn J Infect Dis., 2015; 68(4): 318-320.
 Jessica KO, Jesse DS, Keith SK et al., Strategies for the safe use of colistin, Expert Review of Anti-infective Therapy, 2015; 13(10): 1237-1247.